FREDERICK, MD. Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD) application with the Food and Drug Administration (FDA). The INAD covers the development of the company’s K9MGP product which, when approved, will effectively control an active seizure in dogs that can be used by pet owners at home.
Seizures may have serious effects on the brain and can be a medical emergency. Pet owners often experience significant emotional stress during their dog’s seizure and treatment can be a financial burden. Currently there are no FDA-approved drugs indicated for controlling active seizures in dogs.
Mr. Michael Mesa, CEO and President of MesaGreen Pharmaceutical Company states “currently dog owners have limited choices when confronted with a seizing animal at home and with millions of dogs suffering seizures annually, there is a significant unmet medical need that we intent to fill with K9MGP.”
Michael Podell DVM. MSC, DACVIM (Neurology), Scientific Advisor to MesaGreen Pharmaceutical Company added, “The single most important component that a veterinarian can provide an owner living with an epileptic dog is the ability to feel confident that they can manage an epileptic seizure at home. Providing this opportunity to provide a safe and effective at home rescue therapy will fulfill the criteria to improve not only the life of affected dogs but also their owners by providing the security of knowing they can provide meaningful help”.
Studies under the INAD will provide dosing, safety and effectiveness data that will support a New Animal Drug Application (NADA) for approval to market K9MGP.
MesaGreen Pharmaceutical Company is a small veteran-owned business and is a subsidiary of Mesa Science Associates, Inc. Both companies are located inside the Frederick Innovation and Technology Center on Metropolitan Court in Frederick MD.
Certain information set forth in this press release contains “forward-looking information”, including “future-oriented financial information” and “financial outlook” (collectively referred to herein as forward-looking statements). Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, the (i) projected financial performance of the Company; (ii) completion of, and the use of proceeds from, the sale of the shares being offered hereunder; (iii) the expected development of the Company’s business, projects, and joint ventures; (iv) execution of the Company’s vision and growth strategy, including with respect to future M&A activity and global growth; (v) sources and availability of third-party financing for the Company’s projects; (vi) completion of the Company’s projects that are currently underway, in development or otherwise under consideration; (vi) renewal of the Company’s current customer, supplier and other material agreements; and (vii) future liquidity, working capital, and capital requirements. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Although forward-looking statements contained in this presentation are based upon what management of the Company believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements